[Long term results of vaccination against viral hepatitis B using recombinant vaccine Engerix B].
Among nineteen persons vaccinated against hepatitis B (recombinant Engerix B vaccine) fifteen (80 per cent) have developed anti-HBs (investigated 30 days after the third doses) on the protective level (10 U/l). After three and a half year three of them lost antibodies, and four had anti-HBs at level below 100 U/l. All of them received a booster doses, which resulted in a very high anti-HBs level one month later. Four persons without anti-HBs after the basic vaccination received in turn two booster doses: at the 3rd and 46th month. Only one person of them have remained a non-responder. We suggest to control a level of anti-HBs one month after basic vaccination for individual determination of the term of booster dose.
Juszczyk
J
J
Klinika Chorób Zakaźnych Instytutu Mikrobiologii i Chorób Zakaźnych AM im. K. Marcinkowskiego, Poznaniu.
Barałkiewicz
G
G
D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009784:Occupational Diseases / Q000276:immunology / Q000517:prevention & control; D010564:Personnel, Hospital; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
C075654:Engerix-B; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic
Odległe wyniki szczepienia przeciwko wirusowemu zapaleniu watroby typu B przy uzyciu rekombinowanej szczepionki Engerix B.